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Abstract 
The current treatment of choice for metastatic pancreatic cancer involves single agent 
gemcitabine or combination of gemcitabine with capecitabine and erlotinib (tyrosine 
kinase inhibitor). Only 25-30% of patients respond to this treatment and patients who do 
respond initially ultimately exhibit disease progression. Median survival for pancreatic 
cancer patients has reached a plateau due to inherent and acquired resistance to these 
agents. Key molecular factors implicated in this resistance include: deficiencies in drug 
uptake, alteration of drug targets, activations of DNA repair pathways, resistance to 
apoptosis, and the contribution of the tumor microenvironment. Moreover, for newer 
agents including tyrosine kinase inhibitors, over expression of signaling proteins, 
mutations in kinase domains, activation of alternative pathways, mutations of genes 
downstream of the target, and/or amplification of the target represent key challenges for 
treatment efficacy. Here we will review the contribution of known mechanisms and 
markers of resistance to key pancreatic cancer drug treatments. 
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Introduction 
Pancreatic ductal adenocarcinoma is a devastating disease with an extremely poor 
prognosis. It is characterized by invasiveness, rapid progression and marked resistance to 
treatment. Surgery offers the prospect of cure of disease confined to pancreas but has a 5-
year survival of < 20% [1]. Due to the limitations of early detection, radiological 
procedures and lack of unambiguous diagnostic markers, most patients present with 
locally advanced or metastatic disease.  
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The treatment of locally advanced pancreatic cancer generally utilizes chemoradiation or 
chemotherapy alone. The chemotherapeutic agents used for radiosensitization primarily 
are 5-flurouracil[2] and gemcitabine[3]. As far as treatment of metastatic pancreatic 
cancer is concerned, single agent gemcitabine [4], gemcitabine with erlotinib [5] and 
gemcitabine with capecitabine [6] are three reasonable choices supported by literature 
and clinical-based evidence. Despite extensive research in the last decade into pancreatic 
cancer, the overall survival of patients has not significantly improved. Although there has 
been a slight increase in overall survival with the addition of erlotinib to gemcitabine or 
capecitabine to gemcitabine, the median survival still remains approx 6 months [5]. 
However, only a minority (25-30%) of patients respond to gemcitabine based treatments. 
Patients, who do respond initially, ultimately exhibit disease progression owing to 
acquired resistance to these agents. Several combinations of gemcitabine have been 
evaluated but very few showed additional benefits. This has led to the evaluation of 
gemcitabine free regimen for pancreatic cancer. Recently, a randomized phase III trial 
comparing FOLFIRINOX (5FU/leucovorin, irinotecan and oxaliplatin) to gemcitabine as 
first-line treatment for metastatic pancreatic adenocarcinoma showed significantly longer 
overall survival (10.5 vs 6.9 months), progression-free survival (6.4 vs 3.4 months) and 
higher response rate (27.6% vs 10.9%) than gemcitabine alone. This study suggests 
FOLFIRINOX may emerge as the standard treatment for metastatic pancreatic cancer 
(Conroy et al., 2010 – ASCO presentation, unpublished data) 
In order to overcome resistance phenomena we need to understand pancreatic cancer 
biology and its different mechanism of resistance.  
Extensive research in the last two decades has revealed risk factors associated with 
pancreatic cancer, such as cigarette smoking, environmental factors and genetic 
mutations. Oncogenes, tumor suppressor genes and DNA mismatch genes are altered 
leading to cancer development, progression and chemoresistance. Common oncogenes 
whose expression is altered in pancreatic cancer include k-ras, Akt and A1B1. Tumor 
suppressor genes associated with pancreatic cancer include MAP2K4, TGFBR2, p53 and 
CDKN2A. Inactivation of several DNA mismatch repair genes including human mutL 
homolog1 (MLH1) and breast cancer type 2 susceptibility protein (BRCA2), which code 
for the proteins that correct errors made randomly during DNA replication, have also 
been associated with pancreatic cancer. Table 1 summarizes the observed incidence of 
alterations in these genes in sporadic pancreatic cancer and table 2 summarizes the gene 
altered in familial pancreatic cancer syndromes. 
 Table 1: Pancreatic cancer-associated gene alterations 
Gene Frequency (%) Ref. 
Oncogenes 
k-ras  90 [108] 
Akt2 20 [109] 
A1B1 65 [110]  
HER2  10-60 [91] 
Tumor suppressor  genes 
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p53  30-80  [111] 
CDKN2A/p16INK4 60-80  [112] 
DPC4  50-55  [113] 
PTEN 70 [114] 
LKB/STK11 4 [115] 
DNA mismatch repair genes 
MLH1 3-15 [116] 
BRCA2 7 [116] 
DPC4: Depleted in pancreatic cancer locus 4; HER2: Human epidermal growth factor 
receptor 2. 
Advances in pathological and molecular characterizations have improved our 
understanding of this disease; however, important aspects of pancreatic cancer biology 
remain poorly understood. We still do not understand the exact contribution of specific 
gene mutations in the pathogenesis of pancreatic cancer or the role of stroma in the 
overall pathogenesis and progression of the disease 
Table 2. Familial pancreatic cancer syndromes and associated gene alterations 
Familial pancreatic cancer syndromes           Mutated gene  
Ataxia telangiectasia ATM 
Hereditary 
 pancreatitis 
Cationic trypsinogen 
gene(PRSS1) 
Familial atypical multiple mole melanoma 
syndrome 
CDK2NA, CDK4 
Peutz-Jeghers syndrome STK11 
Hereditary nonpolyposis colorectal cancer 
syndrome 
MLH1, MSH2 
Data taken from [117] 
Resistance to chemotherapeutic drugs is caused by a variety of factors, as shown in 
Figure 1. Inherent resistance is frequently observed in tumors, but as therapy becomes 
more effective with improved efficacy, acquired resistance is common. Acquisition of 
resistance to a range of anticancer drugs is commonly due to over expression of energy-
dependent transporters that efflux anticancer drugs from cells (e.g., multi-drug resistance 
pumps), but other mechanisms of resistance including insensitivity to drug-induced 
apoptosis and induction of drug-detoxifying mechanisms, also play a key role in acquired 
resistance. Effective treatment or circumvention of the inherent resistance of pancreatic 
cancer can only come about through a therapeutically focused understanding the 
pancreatic cancer biology and the underlying mechanisms of resistance. 
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Figure 1. Cellular alteration which can contribute to pancreatic cancer resistance 
 
Cellular alteration which can contribute to pancreatic cancer resistance 
Here we will review our current knowledge of the different mechanisms of inherent and 
acquired resistance to three commonly used anti-cancer agents used in pancreatic cancer; 
gemcitabine, capecitabine and erlotinib.   
Gemcitabine 
Gemcitabine (2’, 2’-difluoro-2’-deoxycytidine, dFdC, Gemzar, [Eli Lilly, IN, USA]) a 
deoxycytidine analogue, is now considered the cornerstone of pancreatic cancer treatment 
as a single agent and in combination with other agents. However, most pancreatic cancer 
patients will exhibit disease progression and treatment provides only a slight survival 
advantage. Gemcitabine also has activity against other cancers including lymphomas and 
solid tumors such as lung, bladder and ovarian cancer [7-10]. 
Cellular metabolic scheme for gemcitabine activation in the cell 
As outlined in Figure 2, gemcitabine is a pro-drug that is phosphorylated by dCK to its 
mononucleotide in a rate limiting step of its cellular anabolism. Subsequent action by 
nucleotide kinases convert gemcitabine monophosphate to its active metabolites, 
gemcitabine diphosphate and gemcitabine triphosphate. Thymidine synthase is inhibited 
by the deaminated form of gemcitabine monophosphate. The de novo DNA synthesis 
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pathway is blocked by gemcitabine diphosphate through inhibition of ribonucleotide 
reductase (RNR) and gemcitabine triphosphate which incorporates itself into DNA and 
RNA, thereby preventing cellular growth and initiating apoptosis [11].  
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Figure 2. Cellular metabolic scheme for gemcitabine activation in the cell. 
Downregulation of dCK and upregulation of RNR (red font) are two common alteration 
in gemcitabine metabolism associated with its resistance.                                                    
dCK: Deoxycytidine kinase; FdUMP: Flourodeoxyuridine monophosphate; RNR: 
ribonucleotide reductase. 
Mechanisms of gemcitabine resistance 
The sensitivity/resistance of cancer cells to gemcitabine cannot be predicted by a single 
factor but may be determined by the balance of several factors. Molecular factors 
associated with this process include: deficiencies in gemcitabine uptake through altered 
nucleoside transporters, limitations of gemcitabine cellular activation/phosphorylation 
enzymes, activation of DNA repair pathways, resistance to apoptosis, altered cell cycle 
and proliferation pathways as well as a transition to a more epithelial to mesenchymal 
transition (EMT) like phenotype. Table 3 summarizes the primary factors which have 
been demonstrated to contribute to gemcitabine resistance. 
Table 3. Summary of factors known to be involved in gemcitabine-resistance. 
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Mechanism Factors Ref. 
Membrane transport mechanisms 
 
hENT-1  
hCNT1 and hCNT3 
[16]                 
[18] 
Enzymes in important in DNA/RNA 
synthesis 
dCK  
RNR 
[19]                    
[118] 
Genes involved in cell cycle regulation, 
proliferation and apoptosis 
Loss of p53 function  
P13K-Akt pathway 
modification 
Src phosphorylation  changes 
Reduced BNIP-3 expression  
Reduced S100A2, S100A4 
exspression 
Increased ILK expression 
Increased CEACM6 
expression  
Epithelial to Mesenchymal 
transition  
[25]  
[31]  
[26]  
[31]  
 
[32] 
[41]                                     
[119]                                                       
[45,120] 
BNIP-3: Bcl-2/adenovirus E1B 19kDa protein interacting protein; CECACM6: 
Carcinoembryonic antigen-related adhesion molecule 6; hCNT: Human concentrative 
nucleoside transporter; hENT1: Human equilibrative nucleoside transporter; ILK: 
Integrin-linked kinase; RNR: Ribonucleotide reductase. 
Transport mechanism across the cell membrane  
Nucleosides are hydrophilic and cannot traverse cell membranes by passive diffusion; 
therefore, specialized transport systems are required for the passage of nucleoside analogs 
in or out of the cell. Two groups of nucleoside transporters have been identified. These 
include human equilibrative nucleoside transporters hENT1 and -2 [12, 13] and human 
concentrative type nucleoside transporters (hCNT) 1, -2 and -3 [14]. 
Several investigators have demonstrated the important role of nucleoside transporters in 
gemcitabine entry into the cells. Using gemcitabine in combination with BIBW22BS, a 
potent inhibitor of facilitated diffusion-mediated nucleoside transport, Jansen et al. found 
a 30-100 fold decrease in the activity of gemcitabine in various human cancer cell lines 
[15]. Similarly Mackey et al. found that cells with a nucleoside transporter deficiency 
were highly resistant to gemcitabine [16]. This study also suggests that the type of 
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nucleoside transporter in a cell may help determine sensitivity/resistance to gemcitabine. 
Several studies have been undertaken in pancreatic cancer to determine the impact of 
these nucleoside transporters in the prognosis of patients. Spratlin et al. have suggested 
that the presence of abundant hENT1 staining within pancreatic tumor cells may be a 
prognostic marker of survival [17]. Patients with uniformly detectable hENT1 had a 
significantly longer survival with gemcitabine treatment (median survival: 13 months) 
than patients with tumors lacking detectable hENT1 (median survival: 4 months). 
Marechal et al. found that not only hENT1, but also hCNT1 and hCNT3 are responsible 
for gemcitabine uptake into cancer cells [18]. In a study of 45 pancreatic adenocarcinoma 
patients treated with gemcitabine as an adjuvant treatment after curative resection, they 
found that patients with high hENT1 expression had significantly longer disease free 
survival and overall survival than patients with low expression. They also found that high 
hCNT3 expression was associated with longer overall survival. This indicates that 
hENT1 and hCNT1 and hCNT3 all play a role in the transport of gemcitabine, and 
deficiency of these transporters may cause innate resistance to this agent. Only a minority 
of patients respond to gemcitabine. These data suggests that it may be possible to select 
patients by determining hENT1 and hCNT1 and hCNT3 expression in tumors. However, 
this hypothesis needs careful examination in prospective randomized studies before 
adoption.  
  
Alterations in sub-cellular targets. 
Alterations in the cellular targets of gemcitabine result in decreased sensitivity to the 
agent. Research in this area has focused on two key enzymes, dCK and RNR.  
Role of dCK in gemcitabine resistance 
In the cell, gemcitabine is phosphorylated by dCK to its monophosphate form. This first 
step in phosphorylation is the rate limiting step for further phosphorylation to active 
metabolites and thus essential for the activation of gemcitabine. Gemcitabine is also 
phosphorylated by TK2 [11].  
Several authors have described a relationship between dCK activity and acquired 
resistance to gemcitabine. Most of these studies were performed in ovarian cancer cell 
lines and acquired resistance was associated with dCK deficiency. Van der Wilt et al. 
studied the effect of dCK gene transfection in dCK deficient gemcitabine-resistant human 
ovarian AG6000 cells [19]. Recovery of dCK activity in these cells by transfection with 
the dCK gene not only increased in vitro sensitivity to gemcitabine, but evaluation of 
same cells cultured as a xenograft in vivo by growth in nude mice also supported the 
important role of dCK in tumor cell sensitivity to gemcitabine.  
Sebastiani et al. explored genetic alterations of  the dCK gene in pancreatic cancer 
patients who progressed on gemcitabine and in 17 pancreatic cancer cell lines and found 
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no mutation in any of the patients or the cell lines, indicating that mutation in the dCK 
gene may not be a frequent mechanism of gemcitabine resistance in human pancreatic 
cancer [20]. However, pre-treatment immunostaining of dCK in pancreatic cancer tissue 
strongly correlated with progression free and overall survival, proving the importance of 
the level of this enzyme in cells in gemcitabine sensitivity. 
Nakano et al. analyzed by RT- PCR  the importance of the ratio of mRNA expression of 
4 proteins, dCK, hENT1 and ribonucleotide reductase M subunit 1 and 2 (RRM1 and 
RRM2), in gemcitabine sensitivity by reverse transcription PCR (RT-PCR) [21]. Through 
an examination of six pancreatic cancer cell lines, they found that the ratio of mRNA 
expression of dCK x hENT1/RRM1 x RRM2 was more indicative of drug sensitivity and 
the higher the ratio the more sensitive the cell line was to gemcitabine and vice versa.  
Role of RNR in gemcitabine resistance 
Inhibition of RNR is one of the self-potentiating mechanisms of gemcitabine action. 
Gemcitabine diphosphate inhibits RNR which results in a decrease in 
deoxyribonucleotide pools, including dCTP, leading to decreased feedback inhibition of 
dCK [11]. As dCTP competes with gemcitabine triphosphate for incorporation into DNA, 
decreased dCTP levels will increase gemcitabine incorporation into DNA. Several 
investigators have described the link between RNR activity and gemcitabine resistance. 
Nakahira et al. found up regulation of RRM1 in the gemcitabine-resistant pancreatic 
cancer cell line, MiaPaCa2-RG, by microarray analysis [22]. Knockdown of RRM1 by 
siRNA reduced MiaPaCa2-RG gemcitabine resistance to that of the parental cell line. 
Furthermore, this observation translated clinically, as patients with high levels of RRM1 
had significantly poorer survival outcome after gemcitabine treatment compared to those 
with low RRM1 levels. Resistance to gemcitabine has also been observed in cells over 
expressing a second sub unit of the RNR complex, RRM2. Duxbury et al. found 
increased  expression of  RRM2 in gemcitabine-resistant PANC-1 cells [23]. Knockdown 
of the M2 subunit gene in pancreatic cancer cells by siRNA enhanced the 
chemosensitivity to gemcitabine. In one study, pretreatment biopsies from unresectable 
pancreatic cancer patients  showed that patients with low tumor RRM2 mRNA levels 
have a better overall outcome compared to patients with high RRM2 mRNA levels [24].    
Gemcitabine resistance: role of cell cycle regulation, apoptosis and EMT genes 
Genes involved in cell cycle regulation, survival and proliferation play a key role in 
pancreatic chemoresistance to anticancer agents, including gemcitabine. p53 is an 
important gene in regulating the cell cycle and functions as a tumor suppressor involved 
in regulating cell growth. Galmarini et al. developed two breast cancer cell lines, MN-1I 
and MDD-2 with MN-1 cells containing wild type p53 and the MDD-2 cell line 
containing a mutant p53 [25]. Exposure to gemcitabine induced a higher degree of 
apoptosis in MN-1 than in MDD-2 cells. This corresponded with suppression of Bcl-2 
and Bcl-xL expression in the wild type p53 cells exposed to gemcitabine, whereas Bcl-2 
levels remained stable and Bcl-xL levels increased in the mutant p53 cells exposed to the 
drug. The authors suggested that loss of p53 function leads to loss of cell cycle control 
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and alterations in the apoptotic cascade, conferring resistance to gemcitabine in cancer 
cell lines displaying the mutant p53 phenotype. 
Duxbury et al. suggested the role of the nonreceptor tyrosine kinase Src in innate and 
acquired resistance to gemcitabine [26]. They developed pancreatic cell lines resistant to 
gemcitabine and found that the resistance was associated with higher Src phosphorylation 
and activity as compared to gemcitabine-sensitive cell lines.  
There is evidence to suggest that activation of antiapoptosis regulating genes may 
contribute to the chemoresistance of pancreatic cancer cells to gemcitabine. In pancreatic 
cancer, expression of the anti-apoptosis gene Bcl-xL leads to shorter patient survival [27]. 
A study by Bold et al. found that cellular overexpression of Bcl-2, a potent inhibitor of 
apoptosis, significantly decreased gemcitabine-induced apoptosis in pancreatic cancer 
cell lines [28]. Transfection of Bcl-2 siRNA of the pancreatic cancer cell line, YAP C 
into nude mice xenograft showed a synergistic interaction with gemcitabine compared to 
gemcitabine alone. Silencing of the Bcl-2 gene also restored sensitivity to gemcitabine in 
vitro [29].  
In contrast, enhanced expression of the pro-apoptotic Bax gene significantly increased the 
sensitivity of the pancreatic cancer cell line, AsPc-1, to gemcitabine and 5FU. Friess et 
al. found that Bax expression in pancreatic tissue was a strong indicator of survival [27].  
Further development of this concept suggests that the ratio of Bax to Bcl-2 may have 
stronger functional significance. Shi et al. found that if the ratio of Bax to Bcl-2 tipped 
towards Bax, that this could  promote apoptosis and be predictive of gemcitabine 
sensitivity [30]. Akada et al. identified the Bcl-2/adenovirus E1B 19kDa protein 
interacting protein (BNIP3), a Bcl-2 family proapoptotic protein as lowly expressed in 
gemcitabine-resistant pancreatic cancer cell lines [31]. BNIP3 expression was 
downregulated in drug resistant pancreatic cancer cell lines and its expression was also 
found to be downregulated by 90% in 21 pancreatic cancer tissue specimens. siRNA-
mediated knockdown of BNIP3 in pancreatic cancer cell line reduces gemcitabine-
induced cytotoxicity in vitro. Mahon et al. identified the upstream genes, S100A2 and 
S100A4 as BNIP3 suppressors in PDAC pancreatic cancer cell lines, with the ability to 
repress exogenous BNIP3 promoter activity in vitro [32]. S100A4 knockdown resulted in 
an increased sensitivity of the resultant cells to gemcitabine treatment, which was 
coupled with an increase in apoptosis and cell cycle arrest.  
Other antiapoptotic signal transduction pathways linked to the chemoresistance of 
pancreatic cancer include PI3K-Akt and NF-κB. The PI3K signaling cascade plays a 
crucial role in the regulation of apoptosis, acting in part via its downstream target Akt in 
several cancer cell types including pancreatic cancer. Gene expression cDNA microarray 
profiling of 15 pancreatic cancer cell lines exposed to gemcitabine revealed alterations in 
levels of seven genes that encode proteins active in the PI3K-Akt pathway [31]. 
 Recent investigations have shown that reduction of PI3K and Akt activity in pancreatic 
cancer cell lines correlates with enhanced gemcitabine-induced apoptosis and antitumor 
activity, suggesting a significant role for these enzymes in mediating drug resistance in 
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pancreatic cancer cells [33]. Inhibition of Akt using a cell-permeable derivative of the 
proapoptotic peptide and Akt antagonist C-terminal modulator protein (CTMP; termed 
TAT-CTMP) in combination with gemcitabine or radiation therapy augments the effects 
of gemcitabine and radiotherapy in vitro and in vivo [34].                                                                               
NF-κB plays an important role in cancer progression and increased expression promotes 
cellular resistance to anticancer therapy. Arlt et al. showed that pancreatic cancer cell 
lines resistant to gemcitabine-induced apoptosis had high basal NF-κB activity [35]. In 
addition, inhibition of NF-κB reduced gemcitabine resistance in these cells. However, the 
PI3K-Akt pathway was not involved in the gemcitabine resistance of these cells, as 
inhibition of PI3K-Akt by LY294002 did not affect gemcitabine-induced apoptosis. 
Yokoi et al. demonstrated that hypoxia can induce gemcitabine resistance in pancreatic 
cancer cells mainly through the PI3K-Akt-NF-κB pathways and partially through the 
MAPK (Erk) signaling pathway [36]. In contrast, other studies have shown that NF-κB 
expression does not correlate with gemcitabine sensitivity; however, knockdown of NK-
κB in vitro and in vivo did potentiate the effects of gemcitabine in sensitive cells but not 
resistant cells [37]. Disruption of NF-κB activity by inhibition of glycogen synthase 
kinase-3 failed to sensitize pancreatic cancer cells to gemcitabine, suggesting that perhaps 
NF-κB may play a minor role in gemcitabine resistance [38]. Clearly, the contribution of 
NF-κB to pancreatic drug resistance is complex and may depend on other factors. 
However the role of inhibition of NF-κB in potentiating gemcitabine induced cytotoxicity 
is well established [39,40]. 
Duxbury et al. suggested a role for integrin-linked kinase (ILK) in gemcitabine 
chemoresistance in pancreatic cancer [41]. ILK facilitates signal transduction between 
extracellular events and important intracellular survival pathways involving protein 
kinase B/Akt. Overexpression of ILK increased cellular gemcitabine chemoresistance, 
whereas ILK knockdown induced chemosensitization via increased caspase 3-mediated 
apoptosis. 
An interesting paper by Liau et al. pointed towards the role of high mobility group 
protein (HMGA1) in pancreatic cancer resistance to chemotherapeutic agent especially 
gemcitabine [42]. HMGA1 is a transcriptional protein complex which forms on 
chromatin and regulates transcription of numerous genes downstream of Ras/ERK 
signaling pathway. Utilizing the MiaPaca2 and BxPc3 cell lines, they found silencing of 
HMGA1 by the use of siRNA increased the chemosensitivity of gemcitabine and forced 
overexpression of HMGA1 promoted resistance to gemcitabine in MiaPaca2. The same 
phenomenon was demonstrated in xenograft nude mice where again silencing of HMGA1 
promoted gemcitabine-induced cytotoxicity and reduces tumour growth [43]. They also 
suggested that HMGA1 mainly works through Akt activation. Emerging evidence 
suggests both molecular and phenotypic associations between gemcitabine resistance and 
the EMT phenotype, pointing towards an interesting mechanism of pancreatic cancer 
resistance. EMT is a process initially seen in the development of the embryo, whereby 
cells lose epithelial characteristics and gain a mesenchymal phenotype. Recent research 
has shown that the EMT may be an important phenomenon in cancer progression; 
epithelial-derived tumor cells switch properties to a more mesenchymal phenotype 
facilitating tumor invasion and metastasis. The epithelial state is characterized by E-
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cadherin and cytokeratin (e.g., cytokeratin 18) expression. Using immunohistochemical 
techniques, Nakajima et al. examined the expression of vimentin, and N- and E-cadherin 
in pancreatic cancer tissue specimens [44]. In epithelial cells, the loss of E-cadherin and 
the increase in N-cadherin expression was found to be associated with a metastatic 
phenotype. Vimentin expression was observed in a few cancer cells of pancreatic primary 
tumors but was substantially expressed in pancreatic cancer liver metastasis. Shah et al. 
developed gemcitabine-resistant pancreatic cancer cell lines displaying spindle-shaped 
morphology, an appearance of pseudopodia and reduced adhesion with increased 
invasion and migration potential [45]. The gemcitabine-resistant cells demonstrated 
increased vimentin and decreased E-cadherin expression. Receptor protein tyrosine 
kinases and c-MET were activated and there was an increase in the expression of the 
stem cell markers CD24, CD44 and epithelial-specific antigen (ESA) in the resistant 
cells. To further elucidate the mechanisms for the acquired EMT phenotype of 
gemcitabine resistant cells, Wang et al. found that Notch-2 and its ligand Jagged-1 were 
highly upregulated in gemcitabine-resistant pancreatic cancer cells [46]. Knockdown of 
Notch lead to a reduction in the invasive and EMT phenotype of the cells, indicating that 
activation of Notch signaling in gemcitabine-resistant cells may be linked to EMT.  
MicroRNAs and gemcitabine resistance 
MicroRNAs (miRNAs) are post-transcriptional regulators that bind to mRNA. Since their 
identification, research has revealed multiple roles for miRNAs in the negative and 
positive regulation of translation and transcription. Several researchers have 
demonstrated the role of miRNA-21 in the chemoresistance of gemcitabine in both 
pancreatic cancer cell lines and patients. Research in this field has established that 
miRNA-21 contributes to pancreatic cancer invasion, metastases and chemoresistance of 
gemcitabine [47]. Giovenetti et al. carried out a study in pancreatic cancer patients and 
found shortened overall survival in individuals with high miRNA-21 expression in both 
metastatic and adjuvant setting [48]. Similarly, inhibitory studies with antisense 
oligonucleotides to miRNA-21 increased apoptosis, arrested cell cycle and sensitized the 
cells to gemcitabine [49]. The roles of other miRNAs are under investigation and 
potentially provide us with new targets for overcoming resistance. 
Contribution of stromal factors to drug resistance 
Pancreatic cancer is characterized by dense desmoplastic reactions which can involve 
adjacent vital structures. Cancer cells are usually surrounded by a dense stroma 
consisting of myofibroblast-like cells, collagen and fibronectin. Several researchers have 
demonstrated the contribution of stromal factors to pancreatic cancer pathogenesis [50]. 
Similarly the role of tumor microenvironment in the innate resistance of pancreatic 
cancer has also been demonstrated [51,52].  
The use of antiangiogenesis drugs has elicited survival benefits in many aggressive 
tumors; however, these inhibitors have failed to produce lasting clinical responses in 
pancreatic cancer patients [53]. A review by Bergers et al. describes the modes of 
resistance to antiangiogenesis drugs by adaptive/evasive resistance [54]. The biological 
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regulatory mechanisms of invasion and angiogenesis, as well as contributory factors in 
the tumor microenvironment, have revealed underlying mechanisms of resistance to 
antiangiogenic therapies. Pancreatic cancer is characterized by its hypoperfusion [55], 
and also proven consistently hypoxic possibly because of hypoperfusion. Failure of most 
of the chemotherapeutic combinations and even newer treatment including cetuximab and 
bevacizumab has led to the idea of hypoperfusion as factor leading to the poor delivery of 
anticancer agents [56]. This concept has been recently demonstrated by Olive et al., who 
found that with the use of inhibitors of hedgehog signaling in genetically engineered nude 
mice with pancreatic cancer, fibrous stroma was depleted, which improved the 
microvascular density and delivery of gemcitabine into the cancer cells [57]. This is a 
very interesting study that could at least partially explain the general resistant behavior of 
pancreatic cancer to anticancer agents. Hedgehog signaling and its aberrant activation are 
well recognized in pancreatic cancer pathogenesis. Feldman et al. also demonstrated that 
inhibition of hedgehog signaling resulted in inhibition of metastatic spread in an 
orthotopic xenograft model [58]. However, practical and experimental limitations mean 
that we have a particularly poor understanding of the role of the pancreatic cancer 
microenvironment in gemcitabine, capecitabine and erlotinib chemoresistance. 
Capecitabine  
Capecitabine (Xeloda®, Genentech, Inc., CA, USA; Roche, Basel Switzerland)) is an 
oral fluoropyrimidine carbamate that is used in colon cancer [59], gastric cancer [60], 
breast cancer [61] and pancreatic cancer [6]. Capecitabine is converted to 5-FU in three 
enzyme-controlled steps as illustrated in Figure 3. The first step is catalyzed by 
carboxylesterase, an enzyme located almost exclusively in the liver, the second step by 
cytidine deaminase, expressed in the liver and various types of tumors, and the last by 
thymidine phosphorylase (PD-ECGF/TP), which is thought be have higher expression in 
tumor than in normal tissues, thus ensuring an enhanced efficacy [62]. Capecitabine has 
potentially two pharmaceutical advantages: enhanced activation at the tumor site and 
decreased drug accumulation in healthy tissues, thereby decreasing systemic toxicity. 
Carboxylesterase
5DFCR
CYd
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5 Flurouracil
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Figure 3. Metabolic conversion of capecitabine to 5-fluorouracil 
5’DFCR: 5’-Deoxy-5-flurocytidine; 5’DFUR: 5’Deoxy-furouridine 
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Metabolic conversion of Capecitabine to 5-fluorouracil 
Capecitabine is orally administered as a prodrug converted to 5’-deoxy-5-flurocytidine 
(5’DFUR), which is ultimately converted into 5-FU in vivo (as shown in Figure 3). 
Therefore, to understand the mechanism of action of capecitabine, it is important to 
understand the mechanism of 5-FU action. 5-FU exerts it anticancer effects through 
inhibition of thymidylate synthase (TS) and incorporation of its metabolites into RNA 
and DNA, as outlined in Figure 3. 
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Figure 4. Cellular metabolic scheme for 5-fluorouracil. 
FdUDP: Flourodeoxyuridine diphosphate; FdUMP: Flourodeoxyuridine monophosphate; 
FdUTP: Flourodeoxyuridine triphosphate; FUDP: Fluorouridine diphosphate;         
FUTP: Fluorouridine triphosphate; FUMP: Fluorouridine monophosphate; OPRT: 
Orotate phosphoribosyltransferase; PRPP: phosphoribosyl pyrophosphate; FUR: 
Fluorouridine; UP: Uridine phosphorylase; UK: Uridine kinase; RR: Ribonucleotide 
reductase; DPD: Dihydropyrimidine dehydrogenase; TK: Thymidine kinase. 
Cellular metabolic scheme for 5-FU 
5-Fluorouracel is converted to three active metabolites: flourodeoxyuridine 
monophosphate (FdUMP), flourodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP), as shown in Figure 4. The mechanism of 5-FU activation is 
conversion to flourodeoxyuridine monophosphate, either directly by orotate 
phosphoribosyltransferase (OPRT) with phosphoribosyl pyrophosphate as the cofactor, or 
indirectly via fluorouridine (FUR) through the sequential action of uridine phosphorylase 
(UP) and uridine kinase. Fluorouridine monophosphate is then phosphorylated to 
fluorouridine triphosphate, which can be either further phosphorylated to the active 
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metabolite FUTP, or converted to fluorodeoxyuridine diphosphate (FdUDP) by RNR. In 
turn, FdUDP can either be phosphorylated or dephosphorylated to generate the active 
metabolites FdUTP and FdUMP, respectively. An alternative activation pathway involves 
the thymidine phosphorylase-catalyzed conversion of 5-FU to fluorodeoxyuridine 
(FUDR), which is then phosphorylated by thymidine kinase (TK) to FdUMP. 
Dihydropyrimidine dehydrogenase (DPD)-mediated conversion of 5-FU to 
dihydrofluorouracil (DHFU) is the rate-limiting step of 5-FU catabolism in normal and 
tumor cells. Up to 80% of administered 5-FU is broken down by DPD in the liver [63].  
We will now discuss the potential mechanisms thought to be involved in innate and 
acquired resistance to capecitabine. Unfortunately, as little research has been conducted 
on capecitabine resistance mechanisms in pancreatic cancer, we must rely on indirect 
evidence gathered from knowledge of capecitabine resistance in other tumor types. Table 
4 summarizes the main known resistance mechanisms to capecitabine and its downstream 
products. 
 
Table 4. Factors involved in capecitabine/5-FU resistance 
Mechanism Marker of resistance Ref 
Membrane transport mechanisms 
 
hENT1 &hENT2  
hCNT1  
Upregulation of MRP5 
Upregulation of MRP8 
[65] 
[64]                    
[68]                          
[69] 
Enzymes in important in DNA/RNA synthesis TP  
DPD  
TS 
[74] 
[78]                         
[79]                          
Genes involved in cell cycle regulation, 
proliferation and apoptosis 
Src kinase activation  
Overexpression NF-κB  
Over expression of antiapoptotic 
gene c-Flip 
[86]  
[84]                          
[84]                         
DPD: Dihydropyrimidine dehydrogenase; hCNT: Human concentrative nucleoside 
transporter; hENT1: Human equilibrative nucleoside transporter; MRP: Multidrug-
resistance protein; TP: Thymidine phosphorylase; TS: Thymidylate synthase. 
Cellular transport mechanisms  
Currently, there is very little information available on the role of transporters in resistance 
to 5'-DFUR (the intermediate product of capecitabine) in pancreatic cancer. Mata et al. 
showed that 5'-DFUR  is a substrate for the nucleoside transporter hCNT1, but not for 
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capecitabine or 5-FU, and its expression conferred sensitivity to the drug in a 
heterologously hCNT1-expressing CHO-K1 cell line [64]. In breast cancer cell lines, 
hENT1 is the main transporter of 5'-DFUR, and deficiency of this protein reduces the 
cytotoxicity of 5'-DFUR [65]. Inhibition of hENT1 has been demonstrated to block most 
of the transcriptional targets of 5'-DFUR action, including genes associated with 
apoptosis and cell cycle progression [66]. Therefore, there is evidence to suggest that 
hENT1 and hCNT1 are both transporters of 5'-DFUR and deficiency of these transporters 
reduces the cytotoxicity of 5'-DFUR. However, expression of these transporters in 
pancreatic cancer cells and its impact on the prognosis of pancreatic cancer has not yet 
been studied.  
Role of efflux pumps in cancer resistance to capecitabine metabolites 
Pancreatic cancer’s intrinsic resistance to established chemotherapy drugs can be 
mediated by multidrug resistance proteins (MRPs) and the multi-drug resistant-1 gene 
(MDR; P-glycoprotein) [67]. However, the contribution of MDR to chemoresistance in 
pancreatic carcinoma is unclear. Hagmann et al. found MRP3, MRP4, and MRP5 were 
upregulated in 5-FU-resistant Capan-1 pancreatic cancer cells [68]. RNAi-mediated 
knockdown of MRP5 resulted in increased sensitivity to 5-FU in pancreatic carcinoma 
cells. Utilizing a PC6 small cell lung cancer cell line Oguri et al. developed resistance to 
5-FU and found that reduced drug sensitivity was associated with over expression of the 
MRP8 gene [69]. 
Sub cellular enzyme targets  
In theory, either a deficiency of enzymes that are responsible for the activation of 
capecitabine intermediates or an increase in levels of enzymes responsible for 
inactivation of capecitabine could confer resistance. Three enzymes demonstrated to be 
involved in resistance to activated capecitabine products are TP, TS and DPD.  
Thymidine phosphorylase is an enzyme present in cancer cells responsible for converting 
5'-DFUR to its active metabolite, 5-FU, and is therefore a limiting factor in the anti-
tumor effects of these drugs. Interestingly, this enzyme is identical to PDGF and also has 
angiogenic activity [70]. Increased pretreatment levels of TP in pancreatic [70] and colon 
[71]  cancer is associated with unfavorable clinical outcome and poorer survival. In breast 
cancer, patients with TP-positive tumors showed a longer time to progression if they 
received taxanes before capecitabine than patients with TP-positive tumors who did not 
receive this treatment, providing evidence that TP expression in breast cancer could 
represent a biomarker of sensitivity to capecitabine treatment [72]. 
Meropol evaluated TP, TS, and DPD levels for their ability to predict response to 
capecitabine treatment in colon cancer [73]. Positive staining for TP by 
immunohistochemistry predicted for significantly higher response rate (65% v 27%) to 
the combination of capecitabine with irinotecan (CAPIRI), and survival that was nearly 
double for patients with TP-negative tumors.  
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Studies have also demonstrated that intratumor levels of TP and DPD are indicators of 
tumor response to capecitabine, and that the ratio rather than the actual expression levels 
of TP or DPD alone is predictive of response to capecitabine treatment [74-76]. Schuller  
et al. showed that increased TP levels resulted in increased intratumoral 5-FU levels, 
thereby enhancing the effect of capecitabine in colorectal tumors [77]. Tsukomoto  et al. 
presented data suggesting that high levels of DPD expression result in lower intratumoral 
5FU levels through increased degradation in vitro [74].  
Recent studies further support a correlation between the ratio of TP:DPD and 
capecitabine response. Ishikwa et al. showed that capecitabine can be effective in tumors 
expressing low TP, if DPD expression is low as well [78]. A recent study investigated TP 
and DPD levels in tumor tissue to assess their clinical significance as indicators for 
selecting colorectal cancer patients for 5'-DFUR-based adjuvant chemotherapy. Results 
showed that patients with high TP but low DPD expression had the best disease-free 
survival, whereas the low TP but high DPD group had the worst survival [75]. As 
capecitabine is ultimately converted in the cells to 5-FU by the action of TP, the 
alteration of enzymes and targets of 5-FU activation may also play a role in chemo-
resistance of capecitabine.   
Another enzyme that has been very extensively studied in the resistance to 5-FU is TS. 
Peters et al. found that initial 5-FU treatment inhibited TS, but prolonged exposure 
induced TS levels [79]. TS is a key enzyme in the synthesis of 2 deoxy5monophosphate 
(dTMP) from 2 deoxyuridine monophosphate (dUMP), for which 
methylinetetrahydrofolate is a methyl donor. TS is an important target of the active 
metabolite of 5-FU, and 5-FU treatment can induce TS expression. Okumara et al. 
suggested that TS mRNA expression level may be a predictor of chemosensitivity to 5-
FU in colon cancer patients as TS mRNA expression was inversely related to 5-FU 
sensitivity [80]. Banerjee et al. found that high levels of TS occur as a result of increased 
copy number or increased translation/transcription, and is associated with intrinsic 
resistance to fluropyrimidines [81]. 
Other enzymes responsible for activation of 5-FU include uridinemonophosphate kinase 
(UMPK) and orotate phosphorylase transferase (OPRT). Decreased levels of these 
enzymes have also been described as a resistance mechanism for 5-FU [82] .UMPK is an 
enzyme that is responsible for conversion of 5-FU to 5FUTP and its incorporation into 
RNA, and it was demonstrated that resistance to bolus 5-FU was associated with lower 
expression of UMPK. However, the activities of other 5-FU-metabolizing enzymes 
remain unchanged. More recently, Koopman et al. found that patients with high OPRT 
expression in stromal cells had a favorable prognosis for overall survival; however, high 
OPRT levels in tumor cells was an unfavorable prognostic parameter for progression-free 
survival and overall survival in the Capecitabine, Irinotecan and Oxaliplatin (CAIRO) 
study for advanced colorectal cancer [83]. 
Contribution of genes involved in cell cycle regulation, proliferation and apoptosis 
to resistance 
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As with gemcitabine, genes involved in apoptosis cell cycle regulation and proliferation 
play an important part in resistance of capecitabine. 
Wang et al. profiled 5-FU-resistant and corresponding parental breast cancer cell lines by 
microarray analysis [84]. Enzymes involved in 5-FU activation were downregulated in 
resistant lines, including TK, UMPK and OPRT. Overexpression of genes involved in 
cell regulation, proliferation and apoptosis such as TS, c-YES, NF-κB, p65 and c-Flip 
were also detected in resistant cells. Cotransfection of NF-κB and p65 cDNA induced 5-
FU resistance in MCF-7 cells corresponding with reduced expression of genes governing 
G1-S and S-phase transition. This phenotype may protect FU-resistant cells from cell 
death induced by incorporation of 5-FU into DNA chains by allowing time to repair 5-FU 
induced damage.    
Maxwell et al. analyzed the 5-FU-resistant H630-R10 and parental H630 colorectal 
cancer cell lines by microarrays and found basal expression levels of SSAT, annexin II, 
thymosin beta-10, and chaperonin-10 and MAT-8 expression dramatically increased in 
the 5-FU-resistant cell line compared with the parental line, suggesting that these genes 
may be useful biomarkers of resistance [85].  
Xin et al. suggested that the activation of antiapoptotic genes after repeated drug 
exposure contributes to chemo-resistance of pancreatic cancer cells towards 5-FU, and 
that blockade of antiapoptotic genes might enhance chemosensitivity in pancreatic cancer 
[30]. Ischenko  et al. developed a 5-FU- resistant pancreatic cancer cell line and tested 
the hypothesis that Src tyrosine kinase inhibition could augment the chemo-sensitivity of 
5-FU-resistant human pancreatic cancer cells to 5-FU [86]. They found that combining 5-
FU and Src kinase inhibitor restored the 5-FU-induced apoptosis in the 5-FU resistant 
cell line. Western blotting and RT-PCR analysis revealed that the expression of TS was 
higher in 5-FU-resistant cells; however, expression decreased significantly after pre-
treatment with Src kinase inhibitor. Furthermore, the combination of 5-FU and Src 
inhibitor decreased the 5-FU-induced activation of EGF receptor (EGFR)-Akt pathway. 
Finally, 5-FU and Src inhibitor substantially decreased the in vivo tumor growth and 
inhibited distant metastases. Taken together, 5-FU chemoresistance can be reversed 
through indirect TS regulation by inhibiting Src tyrosine kinase, which may be linked to 
the inhibition of 5-FU-induced EGFR-Akt activation   
Erlotinib 
Erlotinib (Tarceva®, OSI Pharmaceuticals [NY, USA]/Genentech, Inc, Roche) is a small 
molecule tyrosine kinase inhibitor targeting the intracellular domain of EGFR and 
competes with ATP for binding to the kinase domain, thereby impeding downstream 
signaling.  
Human epidermal growth factor receptor is a member of ErB receptor family of receptor 
tyrosine kinases; it is over expressed 30-65% of pancreatic ductal adenocarcinoma [87] 
and has been implicated in the carcinogenesis of the disease [88]. EGFR overexpression 
is associated with poor prognosis, poorly differentiated histology and a more advanced 
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stage of cancer [89]. Recent studies have also suggested that EGFR may be useful as a 
predictive marker for invasion and metastasis in pancreatic cancer [90].  
Over expression of another member of the EGFR family, HER2, has been observed with 
variable incidence of 10-60% in this disease [91] and overexpression of HER2 is 
inversely related to survival [92].  
It has been established that EGFR signaling pathways deregulation occur through various 
mechanisms including receptor or ligand overexpression, receptor mutation and receptor 
cross-talk [93]. In contrast to receptor homodimerization,  heterodimerization of EGFR 
with HER2 provides a stronger growth stimulus, mediated through two pathways, P13K-
Akt pathways and the Ras-Raf mitogen-activated pathway [94], which leads to a cascade 
of events resulting in cell survival and chemoresistance.. 
Predictability of response to erlotinib in pancreatic cancer 
In contrast to lung cancer, EGFR mutation status and its response to erlotinib has been 
poorly studied. Although a study by Moore et al. showed modest benefit of erlotinib with 
gemcitabine versus gemcitabine alone, a 1.5 to 3.6% frequency of EGFR mutation in 
pancreatic cancer was reported, which is significantly lower than other cancer types [5]. 
A study by Tzeng et al. characterized EGFR mutation in pancreatic adenocarcinoma by 
using 9 pancreatic cancer cell lines and 31 specimens from pancreatic cancer patients, 
and observed that the EGFR tyrosine kinase domain is highly conserved in pancreatic 
cancer [95]. Clearly there needs to be a more significant and clinically focused 
investigation of the predictive value of the EGFR mutation and gene copy number on 
erlotinib response in pancreatic cancer to give a more definitive understanding of the role 
of these alterations in erlotinib sensitivity. 
Frolov et al. found that heterodimerization of EGFR with ERB3 and downstream 
signaling from ERB3 is an important mechanism of carcinogenesis [96]. Miapaca-2 cells, 
which lack ERB3, displayed persistent activation and ongoing proliferation, despite the 
use of erlotinib. Erlotinib treatment inhibited Akt phosphorylation in ERB3-expressing 
cell lines. The same phenomenon was demonstrated by Buck et al. [97]. Their work on 
pancreatic and colon cancer cell line and demonstrated that coexpression of EGFR with 
ERB3 determine the sensitvitty to erlotinib.  
Unfortunately, there have been proportionately few investigations of the mechanisms 
underlying erlotinib resistance in pancreatic cancer, so there is an obvious need for 
further investigation. Therefore, we will review the recognized mechanism of resistance 
to erlotinib and related tyrosine kinase inhibitors in other cancers.  Box 1 summarizes our 
knowledge of erlotinib resistance mechanisms based on a number of different cancer 
types. 
Box 1. Summary of the major known erlotinib resistance mechanisms 
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• Down regulation of PTEN [99]  
• Amplification of  MET [100] 
• Mutation of EGFR or other genes as mechanism of resistance [101] 
• Mutation in downstream EGFR targeting pathway genes [102]     
• Alterations in the expression of related growth factor receptor pathways/proteins 
[106-107] 
 
Overexpression/activation of signaling proteins  
Phosphatase and tensin homolog is a lipid phosphatase and tumor suppressor protein that 
regulates P13K-Akt signaling pathway. The major substrate for PTEN is 
phosphatidylinositol 3, 4, 5-triphosphate, a second messenger of P13K. With the loss of 
PTEN function, phosphatidylinositol 3, 4, 5-triphosphate accumulates in the cell 
membrane and activates Akt increasing its cellular anti-apoptotic function [98]. 
Yamasaki et al. demonstrated that acquired resistance to erlotinib involves the activation 
of phosphorylated Akt (p-Akt) and downregulation of MMAC1/PTEN in the A-431 
epidermoid cancer cell line [99]. Gefitinib is another EGFR inhibitor and Engelmann et 
al. found that amplification of MET causes gefitinib resistance in a gefitinib-resistant lung 
cancer cell line by driving ERBB3 (HER3)–dependent activation of PI3K, a pathway 
thought to be specific to EGFR/ErbBB family receptors [100]. Hence a similar 
phenomenon may also occur with erlotinib. 
Mutation of EGFR or other genes as a mechanism of erlotinib resistance 
Pao et al. undertook a study of lung cancer patients whose disease progressed on erlotinib 
or gefitinib and found, in addition to a drug sensitive mutation in EGFR, a secondary 
mutation in exon 20, which leads to the substitution of methionine for threonine at 
position 790 (T790M) in the kinase domain [101]. This study showed that the secondary 
mutation (T790M) emerges in the resistant subclones in the presence of a drug. 
Interestingly this secondary mutation was not seen in untreated tumor samples. The 
authors showed that this T790M mutation directly confers resistance to other EGFR 
mutants usually sensitive to either erlotinib or gefitinib. This study also showed that 24% 
of the patients who were refractory to erlotinib treatment had a k-ras mutation and none 
of the erlotinib-sensitive tumors had such a mutation. K-ras mutation has been associated 
with primary resistance to erlotinib treatment in non-small-cell lung cancer. In colon 
cancer treatment, a very clear link has been established between the efficacy of EGFR-
targeted treatments and k-ras mutation status [102]. Karapetis et al. undertook a study in 
colon cancer patients and their tumor samples, and assessed whether k-ras mutation 
status is associated with response to cetuximab (EGFR-targeted agent). They found that 
patients with mutated k-ras did not benefit from cetuximab treatment, whereas patients 
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with tumors with wild-type k-ras did [102]. This association has, as yet, not been 
established in pancreatic cancer.  
Role of receptor activation as a mechanism of resistance to erlotinib 
The IGF-1 receptor (IGF-1R) activates many of the same down-stream pathways as 
EGFR and overexpression can lead to carcinogenesis, increased proliferation, 
angiogenesis and metastasis [103]. PI3K-Akt signaling is a critical component of the 
downstream mediation of EGFR and also plays a functional role in IGF-1R signaling 
[103]. Chakravarti et al. identified two glioblastoma cell lines that both overexpressed 
EGFR, but exhibited very different responses to EGFR inhibitors [104]. The resistant cell 
line significantly overexpressed IGF-1R and showed further increases in IGF-1R 
expression in response to EGFR inhibition by AG1478, an EGFR tyrosine kinase 
inhibitor. PI3K-Akt signaling persisted in the resistant cell line in response to AG1478 
treatment, and these cells also maintained their invasive and antiapoptotic characteristics. 
These findings point towards an ability to switch from EGFR signaling to IGF-IR 
signaling in this cell model in the presence of EGFR inhibition. Therefore, inhibiting both 
pathways simultaneously may provide a mechanism to circumvent this ability to switch 
oncogenic drivers, reduce resistance potential, and thereby reduce the growth and 
invasiveness of cancerous cells [105]. 
 Morgillo et al. also pointed towards another interesting phenomenon of erlotinib 
resistance [106]. Their data suggested that hetrodimerization of EGFR/IGF-1R and its 
downstream signaling, including mTOR, stimulated de novo protein synthesis of EGFR 
and survivin with the treatment of erlotinib. They also demonstrated in vitro and in vivo 
that knockdown of surviving, inhibition of IGF-1R activation and suppression of mTOR-
mediated protein synthesis abolished erlotinib resistance.  
Choi et al. worked on non-small-cell lung cancer cell lines (H1650, PC-9, HCC-827) 
containing EGFR mutations that were primarily resistant to tyrosine kinase inhibitors 
[107]. Combined treatment of gefitinib with an IGF-IR inhibitor induced growth 
inhibition, apoptosis and downregulation of phosphorylation of Akt, EGFR and IGF-1R. 
Their data pointed towards combined use of IGF-1R and EGFR inhibitors in patients with 
non-small-cell lung cancers that are refractory to treatment with tyrosine kinase 
inhibitors. 
Taken together, although there is very limited information on the underlying mechanisms 
of erlotinib resistance in pancreatic cancer, extrapolation from observations of erlotinib 
resistance in other tumor backgrounds suggests that it may be feasible to identify markers 
of such resistance, such as k-ras, and/or prevent or overcome resistance by targeting more 
than one point in key growth-driving pathways in the tumor cells. 
 Expert commentary and five year view 
Pancreatic cancer is a disease with extremely poor prognosis. Although the addition of 
erlotinib to gemcitabine has improved median survival, this benefit is quite modest owing 
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to the resistance characteristics of this malignancy. Resistance to pancreatic cancer 
treatment represents a significant clinical and scientific challenge. We have so far 
identified some putative laboratory markers of resistance that could be helpful in properly 
selecting patients for treatment with, for example, gemcitabine and capecitabine, but the 
therapeutic potential/implications of those markers has not been explored in sufficient 
depth to incorporate them into current treatment. There is a clear and distinct need to 
identify and characterize robust markers, especially those which might be expressed in 
serum (owing to the inherent ethical and clinical challenges associated with tumor 
sampling in this particular malignancy). Our selection process for such markers should 
focus specifically on early detection, characterization of the intrinsic sensitivity/resistance 
to standard chemotherapies and early response markers owing to the frequency of 
resistance and the rapid progression of the disease. Looking away from the tumor itself, 
there is an appreciable amount of evidence suggesting that the tumor microenvironment 
plays an important role in this malignancy, and clearly a significant research effort must 
also be directed at this phenomenon to identify potential novel treatment approaches that 
may synergize with more directly tumor-targeting therapies. Advancing these specific 
aspects of pancreatic cancer research will allow us to make much better use of the 
existing arsenal of anticancer drugs and also offers the hope of developing completely 
new, and possibly less toxic, targeted therapeutics for pancreatic cancer treatment, as has 
been the case with some other malignancies.  
Research into better treatment strategies for pancreatic cancer will continue, driven by the 
dearth of knowledge of that particular malignancy, coupled with the slow but inexorable 
global increase in the incidence of the disease.  Five years is a proportionately short time 
in clinical cancer research, so our strategies at this time are likely to be informed by 
extrapolation from our overlapped knowledge with other malignancies and the underlying 
contributions of key alterations in signaling pathways driving the disease and 
confounding treatment response. Extrapolation of existing research suggests that we may 
be in a position to conduct larger-scale clinical evaluations of putative markers and 
especially marker profiles to confirm the presence and magnitude of the disease. Some of 
these putative markers may also provide early, semi-quantitative information on the 
response of the malignancy to treatment. The oncology pharmaceutical industry is awash 
with new drugs targeting new aberrations and pathway alterations, as well as second-
generation agents with improvements in over existing targeted drugs, and it appears 
highly likely that at least some of these agents will be evaluated in regimens in pancreatic 
cancer, hopefully providing increases in rates and extent of patient remission. If we can 
identify agents that give durable response in patients, this may also drive an increased 
acceptance of routine molecular and pathological characterization of the patient’s tumor 
prior to treatment. 
While pancreatic cancer is a particularly challenging malignancy to treat, and its recent 
history has attracted a share of therapeutic “false starts,” extrapolation of our current 
knowledge does give cause for optimism and suggests that significant advances in our 
understanding of the disease and the improvements in treatment options that derive from 
that will be forthcoming, allowing better stratification of patients for treatment and 
improved response. 
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Key issues 
• Median survival of locally advanced pancreatic cancer is 9 months and metastatic 
pancreatic cancer is approximately 6 months. 
• To date we can only detect some putative laboratory markers of resistance but the 
therapeutic potential/implications of those markers have not been explored 
sufficiently to incorporate them into treatment. 
• We are still at an early stage in the understanding of this disease as we are looking 
for key aberrations that bring about the ubiquitous resistance phenotypes. 
• We have no clear indicators of treatment response, particularly for erlotinib, 
despite the emergence of indicators for the treatment efficacy of this agent in 
other malignancies. 
• Better understanding the molecular pathways, role of key genes and role of tissue 
microenvironment in pancreatic cancer resistance will help us to develop new 
targeted therapies with improved efficacy. 
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